Urinary biopyrrins levels are elevated in relation to severity of heart failure
Jun Hokamaki, MD*,
Hiroaki Kawano, MD*,*,
Michihiro Yoshimura, MD*,
Hirofumi Soejima, MD*,
Shinzo Miyamoto, MD*,
Ichiro Kajiwara, MD*,
Sunao Kojima, MD*,
Tomohiro Sakamoto, MD*,
Seigo Sugiyama, MD*,
Nobutaka Hirai, MD*,
Hideki Shimomura, MD ,
Yasuhiro Nagayoshi, MD ,
Kenichi Tsujita, MD ,
Izuru Shioji, BS ,
Shinya Sasaki, BS and
Hisao Ogawa, MD*
* Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto, Japan
Division of Cardiology, Fukuoka Tokushukai Hospital, Fukuoka, Japan
Shino-Test Corporation, Tokyo, Japan

View larger version (24K):
[in a new window]
|
Figure 1 Comparison of urinary levels of biopyrrins/creatinine among the patients in New York Heart Association (NYHA) functional classes I, II, and III/IV and controls. The horizontal line in the box represents the median value; the boxed area is the interquartile range; and the whiskers are the 10% to 90% range.
|
|

View larger version (19K):
[in a new window]
|
Figure 2 Correlation between log biopyrrins/creatinine levels and log B-type natriuretic peptide (BNP) levels.
|
|

View larger version (15K):
[in a new window]
|
Figure 3 (A) Bar graphs comparing New York Heart Association (NYHA) functional classes before and after the active treatment of heart failure (mean ± SEM). (B) Box plots of urinary biopyrrins/creatinine levels before and after the active treatment of heart failure. The horizontal line in the box represents the median value; the boxed area is the interquartile range; and the whiskers are the 10% to 90% range.
|
|
|